English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, February 29, 2024
エーザイ、第18回アルツハイマー・パーキンソン病学会(AD/PDTM2024)において、レカネマブをはじめとするアルツハイマー病に関する最新研究成果を発表
Wednesday, February 21, 2024
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Tuesday, February 20, 2024
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Friday, February 16, 2024
エーザイ、「メトジェクト(R)皮下注ペン」(一般名:メトトレキサート)が日本においてペン型自動注入器注射剤の承認を取得
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Thursday, February 1, 2024
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Friday, January 26, 2024
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Thursday, January 18, 2024
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Wednesday, January 17, 2024
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
Tuesday, January 16, 2024
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575